

PRESS RELEASE
27 December 2022 17:10:00 CET



ProstaLund signs distribution agreement for Italy

ProstaLund AB has signed an exclusive distribution agreement with the Italian company DISTRIBUZIONE BIOMEDICALI ITALIA, DBI srl. The agreement is expected to generate revenues of at least SEK 1.5 million during the first two years of the agreement period.

Earlier this year, ProstaLund began internationalization outside the Nordic region and has signed distribution agreements for, among others, the UK and Spain in Europe. The next step in this process is now being taken when a distribution agreement for ProstaLund's Schelin Catheter and CoreFlow – Soft Stent has been signed for Italy with Distribuzione Biomedicali Italia, DBI srl.

DBI is already the exclusive distributor throughout Italy for Boston Scientific's product lines in urology, including the equipment, water vapor and green laser, to treat benign prostatic hyperplasia. With the help of ProstaLund's products, DBI's existing customers can now be offered a holistic concept that means that the treatments can be performed under local anesthesia and thereby save resources.

During the fall, ProstaLund introduced the Schelin Catheter and CoreFlow – Soft Stent at a handful of clinics in Italy with very good results. The partnership with DBI enables the introduction to be significantly accelerated.

"After the initial very good results, we have been actively looking for a partner in Italy to be able to address the market faster. The collaboration with DBI is probably as close to a perfect marriage as you can get.", says CEO Johan Wennerholm in a comment.

For further information, please contact:

Johan Wennerholm, CEO
Tel. +46 (0) 730 429997
Email: johan.wennerholm@prostalund.com



PRESS RELEASE
27 December 2022 17:10:00 CET

About ProstaLund

ProstaLund AB is a Swedish medical technology company and a leading developer and manufacturer of innovative urological devices and treatments. The company's lead product, CoreTherm, is a patented Thermotherapy treatment method for Benign Prostatic Hyperplasia (BPH) which can be tailored to suit the needs of each individual patient. CoreTherm is used today in hospitals and clinics in Sweden and worldwide. ProstaLund is listed on the Nasdaq First North Growth Market.

Certified Adviser:

Västra Hamnen Corporate Finance AB

Phone: +46 40 200 250

E-mail: ca@vhcorp.se

This information is information that ProstaLund AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2022-12-27 17:10 CET.

Attachments

ProstaLund signs distribution agreement for Italy